par Bentin, Jacques 
Référence Revue médicale de Bruxelles, 14, 6, page (175-181)
Publication Publié, 1993
Référence Revue médicale de Bruxelles, 14, 6, page (175-181)
Publication Publié, 1993
Article révisé par les pairs
| Résumé : | Rheumatoid arthritis (RA) is a chronic articular inflammatory disease of unknown aetiology. The therapeutic approach can be achieved at different levels: 1) symptomatic treatment with nonsteroidal antiinflammatory drugs which can relieve articular pain and stiffness, 2) second-line drugs (or DMARD, for Disease Modifying Anti-Rheumatic Drug) selected for their capacity to slow the rheumatoid process. During this last decade, sulfasalazine and methotrexate became an alternative choice to the 'classical' slow-acting antirheumatic drugs such as gold. D-penicillamine or antimalarials. The extensive progress in basic immunology and especially in the immunopathology of RA has allowed the elaboration of a new approach to immunotherapy, aimed at molecular targets on cells from the 'specific immunity' system or against mediators of the inflammatory process, such as the cytokines. |
